Navigation Links
CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market
Date:7/8/2008

According to CBDM.T®, The market and business intelligence company, the enzyme market is significant and estimated at €3.4 billion with an annual growth of about 6.5 to 10%. Enzymes are sold in many different industry segments. These segments are Detergents, Food, Feed, Technical, Pharmaceutical, Microorganisms and Biofuels.

Paris (PRWEB) July 8, 2008 -- According to CBDM.T®, The market and business intelligence company, the enzyme market is significant and estimated at € 3.4 billion with an annual growth of about 6.5 to 10%. Enzyme products such as Insulin were the first biotech product marketed in the 70's. While enzymes are present everywhere and come in thousands of different forms, there are still only about 25 of them which have actually been industrialised and commercialised. They include Amylase, Proteinase, Lipase, Cellulase, Glycomylase, Glucose Isomerase, Chymosin, Lactase, Pullulanase and Xylanase.

Some countries have a better developed enzyme industry than others, so descriptions of these countries and the nature of the environment they provide for upcoming businesses is given in this market review. In some countries, the industry was developed with support from the state from as early as the 1980's. These are countries such as Denmark, USA and Brazil. The real breakthrough in the industry happened during the 1970s. A new technology was developed, recombinant biotechnology, and this permitted biochemists to create and modify molecules at an unprecedented level.

Enzymes are sold in many different industry segments. These segments are Detergents, Food, Feed, Technical, Pharmaceutical, Microorganisms and Biofuel. For example in the feed industry, enzymes help pigs or chickens digest their food better, which in the end helps producing better meat, while using smaller amounts of fodder. These segments are thoroughly described in this enzyme market review, looking at market sizes, growth and, while looking at global and key market drivers for each segment are also identified and analyzed.

Biofuel is dealt with in particular depth, since it is a potentially large segment for the future. The global Biofuel market (biodiesel derived from vegetable oil and ethanol derived from sugar or starch) was estimated to be worth €25 billion in 2007.

Biocatalysis is also more frequently applied by chemical companies, since it is the pertinent technology for the manufacturing of chiral drugs and sometimes for oil-based chemistry substitution. Enzymes are a key element in performing biocatalysis (biocatalysts are in fact enzymes). This means that biocatalysis will probably be a significant segment in the future enzyme market. This promising market segment is difficult to estimate. But we know that this market segment will affect the market of catalysts estimated by CBDM.T® at more than $7 billion."This explains why some enzyme producers such as Novozymes are investing more and more in the development of this field" says Philippe Tramoy, managing partner.

Key players are: Novozymes, Danisco, Genencor, Verenium, Syngenta, Monsanto, Dyadic, Codexis, Cargill, Diversa, ADM, Dow, IEP, DSM, Genzyme, BASF, Altus, Biocon, Henkel, Roche, Sanofi, Solvay, Direvo, Maxygen...

If you need more information about CBDM.T® Enzyme Market Review, please contact us at contact @ cbdmt.com.

CBDM.T® - Market and Business Intelligence - is a market and business intelligence company with offices in France and in Israel. As an advisory services company, CBDM.T® boosts companies to develop revenue and growth by providing business and marketing services in the life science and biotech markets (market survey, market scouting, business development and strategic supports).

For more information:
CBDM.T® Market and Business Intelligence
88-90 rue de la Mare
Fr-75020 Paris - France
Tel : +33 1 4474 7957
Email : contact @ cbdmt.com
Web site : CBDM.T®

CBDM.T® - Israel
POBox 6235
Netanya - 42490 - Israel
Tel: +972 52 3316190

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
2. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
3. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
4. Competition Alive in the Global Spine Market
5. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
6. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
7. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
8. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
9. Mega-Brand Success: Effective Market Strategy and Tactics
10. Bioheart, Inc. to Transfer to Nasdaq Capital Market
11. GE Energy to market SNS-developed detector electronics system
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CBDM.T, The Market and Business Intelligence Company Reviews The Enzyme Market 
(Date:2/28/2017)... ... February 28, 2017 , ... Surface Plasmon Resonance (SPR) is ... optical phenomenon that is sensitive to changes in the dielectric properties of the medium ... changes in refractive index occurring up to 300 nm above the metal surface (Au) ...
(Date:2/28/2017)... 2017  Phosphorus, a computational genomics and clinical ... the Phosphorus Scientific Advisory Board, an established group ... the company on the development of new products ... visit http://phosphorus.com/about-us/ to learn more about ... gathered some of the top leaders in the ...
(Date:2/28/2017)... 28, 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases ... fourth quarter and full year ended December 31, ... recent business and clinical highlights. "During ... development pipeline by starting five clinical trials across ...
(Date:2/28/2017)... MA (PRWEB) , ... February 28, 2017 , ... ... clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial Travel ... celebrating 15 years of meeting this unique need within the biotechnology and pharmaceutical ...
Breaking Biology Technology:
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):